2026年全球肝炎报告

Globalhepatitisreport2026 Global hepatitis report 2026 ISBN 978-92-4-012238-3 (electronic version)ISBN 978-92-4-012239-0 (print version) © World Health Organization2026 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0IGOlicence (CCBY-NC-SA3.0IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, providedthework is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses anyspecific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you mustlicense your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you shouldadd the following disclaimer along with the suggested citation:“This translation was not created by the World Health Organi-zation (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be thebinding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of theWorld Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation.Global hepatitis report 2026. Geneva: World Health Organization;2026. Licence:CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available athttps://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders. To submitrequests for commercial use and queries on rights and licensing, seehttps://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures orimages, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from thecopyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solelywith the user. General disclaimers.The designations employed and the presentation of the material in this publication do not imply theexpression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or areaor of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps representapproximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recom-mended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the namesof proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, thepublished material is being distributed without warranty of any kind, either expressed or implied. The responsibility for theinterpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. Designed by minimum graphics.Cover design by Irwin Law. Contents AcknowledgementsviiAbbreviationsxChapter 1.Introduction1Chapter 2.Global commitments, strategies and targets7Chapter 3.Epidemic status and trends11Chapter 4.Prevention, diagnosis and treatment37Chapter 5.The road to elimination61References71Annex 1.Methodological notes77Annex 2.The global hepatitis reporting process79Annex 3.World Health Assembly resolutions on viral hepatitis81 Dr Tedros Adhanom GhebreyesusDirector-GeneralWorld Health Organization TheWHO Global hepatitis reportunderscores both encouraging progressand an urgent need for acceleration. While countries that have strengthenedpolitical commitment are demonstrating tangible results, overall progress remains tooslow and uneven to meet the 2030 elimination targets. This report affirms that the tools and strategies required to eliminate viral hepatitis asa public health threat are firmly established. High coverage of the hepatitis B vaccinehas marked a major preventive success, while the advent of highly effective direct-acting antivirals has transformed hepatitis C treatment, achieving cure ratesexceeding 95%. Improvements in blood safety and injection practices have furtherreduced transmission risks, reinforcing that elimination is achievable. However, despite these advances, the global response has yet to match the scale of thechallenge. In many countries, efforts remain at an early stage, constrained by limiteddata, insufficient investment and uneven implementation. This report calls for urgent recalibration and renewed commitment from all countriesto scale up prevention, diagnosis and treatment. By closing critical gaps and seizingthe